GTN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelGetinge’s installed-base services and consumables create repeat purchasing beyond initial equipment sales. This supports revenue visibility, deepens customer relationships, and can improve lifecycle economics as its hospital and life-science customer base expands.
Cash GenerationStrong operating and free cash flow indicates that reported earnings are converting into internally generated funds. This provides capacity to support service infrastructure, invest in products, manage obligations, and fund growth without relying as heavily on external financing.
Improving ProfitabilityThe latest period shows a constructive combination of revenue expansion and improved profitability versus 2024–2025. If maintained, this stronger earnings base can increase reinvestment capacity and reinforce Getinge’s competitive position across healthcare and life-science markets.
Bears Say
Margin DurabilityAlthough profitability has recovered from the 2024–2025 period, margins remain below earlier peaks. This indicates that the recent improvement has not yet restored prior earnings efficiency, leaving future results sensitive to mix, costs, or pricing pressure.
Higher LeverageLeverage remains manageable, but its increase has reduced financial flexibility compared with earlier years. A higher debt burden can constrain capital allocation and leave less room to absorb weaker operating performance while maintaining investment in products and customer support.
Cash Flow VolatilityThe latest cash generation is strong, but the uneven multi-year pattern shows that conversion has not been consistently stable. Such variability can make planning and investment decisions less predictable, particularly when equipment demand and customer spending cycles change.
Getinge News
GTN FAQ
What was Getinge’s price range in the past 12 months?
Currently, no data Available
What is Getinge’s market cap?
Getinge’s market cap is CHF5.89B.
When is Getinge’s upcoming earnings report date?
Getinge’s upcoming earnings report date is Jan 26, 2027 which is in 96 days.
How were Getinge’s earnings last quarter?
Getinge released its earnings results on Oct 21, 2026. The company reported CHF0.258 earnings per share for the quarter, beating the consensus estimate of CHF0.214 by CHF0.045.
Is Getinge overvalued?
According to Wall Street analysts Getinge’s price is currently Undervalued.
Does Getinge pay dividends?
Getinge does not currently pay dividends.
What is Getinge’s EPS estimate?
Getinge’s EPS estimate is 0.41.
How many shares outstanding does Getinge have?
Getinge has 254,152,370 shares outstanding.
What happened to Getinge’s price movement after its last earnings report?
Getinge reported an EPS of CHF0.258 in its last earnings report, beating expectations of CHF0.214. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Getinge?
Currently, no hedge funds are holding shares in CH:GTN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Getinge
Getinge AB, founded in 1904 and headquartered in Gothenburg, Sweden, is a prominent global supplier of medical technology solutions. The company's extensive portfolio is designed for critical healthcare environments, including operating rooms, intensive care units, and sterile processing facilities. Its operations are divided into three core segments: Acute Care Therapies, Life Science, and Surgical Workflows. Getinge offers a comprehensive array of specialized equipment and systems. This encompasses advanced solutions for sterile processing and containment, such as sterilizers, washers, isolators, and automated logistic systems. For the life sciences sector, they provide bioreactors, bioprocess control systems, and associated analytics tools. Within acute care and surgical settings, their offerings range from anesthesia machines, specialized monitoring systems, and various disposables, to instruments for cardiac surgery (like beating heart stabilizers), mechanical ventilation products, and extracorporeal life support (ECMO) solutions. Additionally, Getinge provides infrastructure for operating rooms, including lighting, tables, modular systems, and integrated management tools, alongside products for cleaning, disinfection, packaging, and comprehensive sterile supply management. Their product line further extends to diverse catheters (thoracic, endovascular), endoscopic vessel harvesting systems, patient flow and transport solutions, and specialized devices for vascular and cardiothoracic surgery. The company distributes its broad range of products globally through its proprietary sales companies, as well as via agents and distributors, serving markets across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region.
GTN Stock 12 Month Forecast
Average Price Target
CHF21.25
BONESUPPORT HOLDING AB
―
Xvivo Perfusion AB
―
Bactiguard Holding AB
―
Sectra AB Class B
―
Sedana Medical AB
―









